{
  "doc_id": "RECOTESTMOLPOUM25_CBNPC_tests_moléculaires",
  "created_date": "2023",
  "country": "FR",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "JANUARY ACTUA",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "SLEITNERÉFÉR",
      "text": "TE",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "ER 2023",
      "text": "ALIZATION 2024",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "/ Referenced",
      "text": "PA D’U",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "BR",
      "text": "NO CE / AT AT ’U",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "RO",
      "text": "tiques tiques ATTEINTS",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "CER",
      "text": "cancer cancer (INCa) cancer. cancer.",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Cancer Cancer Institute",
      "text": "RICOUSSE, RICOUSSE, PhD",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "NOTE TO READERS",
      "text": "turquoise turquoise (August 2024). as as follows: cancer cancer / treatments treatments / this this document",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "SUMMARY",
      "text": "...INSTRUCTIONS INSTRUCTIONS ...",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "ABBREVIATIONS",
      "text": "AAC: activity activity AAP: pathogen_pathogen_pharmaceus: pathophysiology: pathogenesis: pharmacokinetics: pharyngology: phytogenetics: rheumatology: phenogenetics : pharmacology: RNA: medication / pharmaceutics: cytotoxicology: BRAF: B-R",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "CONTEXT",
      "text": "_DAM_MIB_RELT_R_C_DR_N_SIM_Receptor _DAM_MIB_RELT_R_C_DR_N_SIM_Receptor _DOM_SEM_RETH_S_DM_Stimulatory_Synthesis_SYNTHERAPY_M_STYR_S; Health Health (HAS) Insurance Insurance (CNAM) CNAM. CNAM.",
      "start_page": 5,
      "end_page": 6
    },
    {
      "heading": "of of biomarkers",
      "text": "following following techniques: McRNA-mediated molecular bioassay; MRS-based molecular bioanalytics; «McNase»; ’McNA-based bioassays; âMachine-mediated mucosal genomics; and âDNAseq] following following issues: of of opportunity; meeting meeting (RCP) and/trials. trials.",
      "start_page": 6,
      "end_page": 7
    },
    {
      "heading": "Updated August 2024",
      "text": "to to _; mutations mutations (4. 4.): mutations __MEDTERM14_insertion exon_: indication, indication, - is is positive: _MED",
      "start_page": 7,
      "end_page": 10
    },
    {
      "heading": "neoadjuvant neoadjuvant treatment",
      "text": "resectable resectable (8th 8th TNM), threshold threshold 1% with with __med).",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "adjuvant adjuvant treatment",
      "text": "be be performed: deletion. deletion.",
      "start_page": 10,
      "end_page": 10
    },
    {
      "heading": "To watch:",
      "text": "adjunctival adjunctival MDS: Adjunctional MDS.",
      "start_page": 10,
      "end_page": 11
    },
    {
      "heading": "1. PD-L1",
      "text": "received received (epidermoid or non-spidermoid), cells cells (the the NCCN). In fact: to to 1% option. option.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "2. EGFR",
      "text": "_Medterm1__ _Medterm1__ (21 21 research).",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Conclusion",
      "text": "PD-L1 PD-L1 (non-squab non-squab cancers) mutahons mutahons (to to 21). chemotherapy. chemotherapy.",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "stage stage (stage IV)",
      "text": "the the NNDPCs’s_cases_",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "1. PD-L1",
      "text": "IHC_reimbursed IHC_reimbursed (and and NICE). types types (epidermal and non-epidermoid). to to 50%, __ME. __ME.",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "2. EGFR",
      "text": "the the _MEDERM;",
      "start_page": 12,
      "end_page": 12
    },
    {
      "heading": "and and __MedTERM2__",
      "text": "__MEDM_ __MEDM_ (NCCN, NCCN, CAP+ and NICE) and __MERM_(the the ESMO) _MERM4 _MERM4 (or or CPN) used. used.",
      "start_page": 13,
      "end_page": 13
    },
    {
      "heading": "4. Multiplexed tests",
      "text": "Nov Nov 30;389(22):2039- EGFR EGFR (to to 21) HER2 HER2 /involving involving __",
      "start_page": 13,
      "end_page": 16
    },
    {
      "heading": "targeted targeted therapy",
      "text": "BRA_C_CED_C BRA_C_CED_C Note: criteria criteria apply: material material (first first time); life. life.",
      "start_page": 16,
      "end_page": 17
    },
    {
      "heading": "Conclusions",
      "text": "defined defined as: __STD1; -cell. cell. MID_Results: Mutations: multiplexed multiplexed cell; Resulting: »MID_Proceedings: cells, cells, NDRM_Searching: CPR CPR and/on on local/of of treatment: For advanced/expression expression if",
      "start_page": 17,
      "end_page": 18
    },
    {
      "heading": "Methodology",
      "text": "clinical clinical trials: clinical trials; international international providers: 2022 2022 (in in 2020; Cancer Cancer 2015), Lung Lung Cancer/Guidelines Guidelines 2018; been been consulted: updated. updated.",
      "start_page": 19,
      "end_page": 20
    },
    {
      "heading": "in in 2022",
      "text": "conclusion conclusion (by by INCa). each each recommendation:",
      "start_page": 20,
      "end_page": 20
    },
    {
      "heading": "Early stage",
      "text": "EGFR EGFR (L858R and del19)",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Locally Advanced Stadium",
      "text": "EGFR EGFR (to to 21)",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Metastatic stage",
      "text": "DNA DNA and/rendering rendering time",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "targeted targeted therapy",
      "text": "liquid liquid biopsy",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "the the document",
      "text": "Clear Clear Document",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Update 2024",
      "text": "2023 2023 (your international recommendations). cells. cells.",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Average % of responses 7",
      "text": "molecular molecular tests",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Participants",
      "text": "specialists. specialists.",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "and and pathologists",
      "text": "Pr Michèle BEAU-FALLER*, Anne Anne CAYRE*, Véronique Véronique DALSTEIN*, Marc Marc DENIS*,Jacqueline Jacqueline LEHMANN-CHE*, APHP Saint-Louis, Paris",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "Clinicians",
      "text": "Pr Nicolas GIRARD*, Marie Marie WISLEZ*, Gérard Gérard ZALCMAN*, ApHP Bichat, Paris",
      "start_page": 22,
      "end_page": 22
    },
    {
      "heading": "*the the update",
      "text": "interest interest (DPI) association. association.",
      "start_page": 22,
      "end_page": 23
    },
    {
      "heading": "in in 2022",
      "text": "pneumologists. pneumologists.",
      "start_page": 23,
      "end_page": 23
    },
    {
      "heading": "List of reviewers",
      "text": "Physicopathology Physicopathology & lung lung cancer: Ouest Ouest eine- Saint-Herblain Saint-Herblain -Saint-Denis Villeurbanne",
      "start_page": 23,
      "end_page": 24
    },
    {
      "heading": "ANNEXES",
      "text": "traitem traitem 19",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "CAP CAP 2018",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "CAP CAP 2018",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "CAP CAP 2018",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN NCCN 2023",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN 2024",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN NCCN 2023",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO 2023",
      "text": "14 14 T_P_T",
      "start_page": 25,
      "end_page": 26
    },
    {
      "heading": "ESMO 2023",
      "text": "NCCN2024",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "ESMO 2023",
      "text": "_TERMED_ME_TERME_ME. _TERMED_ME_TERME_ME._TERMS_TERSM_ME>cell cell tumours; mucosal mucosal mutations; adjacatory adjacatory mucositis; mucus-mediated mucus-mediated mucosa; adjacculatory adjacculatory mucosology; mucoplasmic mucoplasmic mucososis; andjaccionational andjaccionational mucosae; adjacholic adjacholic mucosia; mucosopathy mucosopathy mucosemia; __MEDTERM48_Tumour __MEDTERM48_Tumour (determined as first_IHC); as as therapy: indicated indicated as: - Bronchial Bronchial Cancer: Precision Precision Treatments",
      "start_page": 26,
      "end_page": 30
    },
    {
      "heading": "Merger involving ROS1",
      "text": "__Medterm4__ __Medterm4__ (__MEDDERM4_+), inhibitors. inhibitors.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "Merger involving RET",
      "text": "of of __medterm2__",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "BRAF Mutation V600E",
      "text": "__medterm0__. __medterm0__.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "of of KRAS",
      "text": "cancer cancer (NSCLC) disease. disease.",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)",
      "text": "cells cells (PD-L1-50%), at at 1% __MDTERM20_ __MDTERM20_ - severe severe morbidity55; and - option option Non-advancing/sought. sought.",
      "start_page": 31,
      "end_page": 35
    },
    {
      "heading": "Mutation KRAS G12C",
      "text": "lung lung cancer: treatment treatment with",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "adagrasib (AAC)",
      "text": "taxel. taxel. (side side effects)",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "jump jump MET",
      "text": "without without immunotherapy",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "of of c-__MEDSTERM0_",
      "text": "Advanced non-squamous CBNPC/metastatic relapse/refractory: telisotuzumab - of of treatment;",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "vedotin (AAC) - by by IHC;",
      "text": "- EGFR. EGFR.",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Merging of ROS1",
      "text": "patients patients with",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Fusion of NTRK1/2/3",
      "text": "the the NTRK1/2/line line of",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "(AAFC)",
      "text": "treatment.",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Merging of RET",
      "text": "cancer cancer (NSCLC) treatment. treatment.",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "Clinical Clinical Trials",
      "text": "centre centre (CLIP2 2024-2029) following following page: multilocations. multilocations.",
      "start_page": 36,
      "end_page": 36
    },
    {
      "heading": "early early stage",
      "text": "D. D., I. I., L. L., E. E., 1. 1., Ther. Ther. (D. D., L. L., H. H., J.A., B. B., B.S., C.F., A.T., D.C., 1. 1., 8. 8., 3. 3., 4. 4., 7. 7., 5. 5., 6. 6., 11. 11., Gupta Gupta RG: __MEDMME___ME_, __MEDMME___ME_, _MEDTERM_M: __MERM_, __DERM_ME__Bermer : __STERM_: _TERMME__: _TERMEM___Berber : pharma pharma TYPE: _MERM",
      "start_page": 37,
      "end_page": 45
    },
    {
      "heading": "of of DM",
      "text": "BPH, IHC: fusions, fusions, NGS: S. S., C. C., diagnostics, diagnostics, Qiagen",
      "start_page": 45,
      "end_page": 46
    },
    {
      "heading": "MARCH MARCH 2025",
      "text": "more more information",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "cancer.fr",
      "text": "Tel. Tel.: +33 (1) 50 50 00",
      "start_page": 47,
      "end_page": 47
    },
    {
      "heading": "heading heading CER> (column 1)",
      "text": "Row 1:\nRowRow 2:\nRow",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading CER> (column 2)",
      "text": "Row 1:\n Row 2:\n2024 2024 / Reference PA D’CE CE / Row",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading CER> (column 3)",
      "text": "Row 1:\n Row 2:\nére AT ’Row",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading CER> (column 4)",
      "text": "Row 1:\n Row 2:\nRow",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading CER> (column 5)",
      "text": "Row 1:\n Row 2:\nRow",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading CER> (column 6)",
      "text": "Row 1:\n Row 2:\nRow",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading CER> (column 7)",
      "text": "Row 1:\n Row 2:\nRow",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "August August 2024>",
      "text": "Row1: Pathology. Pathology. Row2: Result Pathology (Result pathology, pathology) Recommendation pathology.",
      "start_page": 7,
      "end_page": 7
    },
    {
      "heading": "heading heading Conclusion>",
      "text": "Row 1:\nConclusionsRow 2:\nFor neoadjuvant therapy:Row 3:\nRowRow 4:\nAdjuvant treatment:row 5: for for Row8:",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "heading heading Conclusion>",
      "text": "Row 1:\nConclusionRow 2:\nRowRow 3:\nexpression expression (non-squab non-squab cancers) RowRow 4:\n__MEDTERM0_ __MEDTERM0_ (be be available).",
      "start_page": 11,
      "end_page": 11
    },
    {
      "heading": "Multiplexed Multiplexed tests> (from previous page)",
      "text": "Row 1:\nRowRow 2:\nEGFR EGFR (to to 21) of of HER2/of of _MEDTERMM1__NGD",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "heading heading Conclusions>",
      "text": "Row 1:\nConclusions Row-Row-Regular-Raw-Relationship: RowRow 3:\nPD-L1 PD-L1 (including for CBNPC-Squamous-Rawn-Rrow-Rown-Rhine-Rhode-RHole-Rhyme-RHO-RowRow 25:\nof of ___MEDTERM0_;Row 26:\nRNAseq. RNAseq.",
      "start_page": 17,
      "end_page": 17
    },
    {
      "heading": "heading heading Conclusions> (from previous page)",
      "text": "Row 1:\nIf a Row_Row-M_Raw-Row_R0_R2_R_R3_R9_R6_R5_R8_R7_R4_R1_R12_R10_R14_R11_R15_R26_R27_R28_R23_R20_R22_R24_R25_R29_R13_R21_R16_R18_R30_R19_R50_R09_R32_R\"R6-R28-R6 -R6 _R6:RowRow 23:\nRowRow 24:\n°RowRow 25:\nRowRow 26:\n»and/the the local/national absence.",
      "start_page": 18,
      "end_page": 18
    },
    {
      "heading": "Average Average % of answers 7>",
      "text": "Row 1:\nResult Row8:Row8 Row2: Row8, Row4:row8, Row7 Row3:__MEDTERM0_ __MEDTERM0_ (L858R and del19) Row5:RR8_:WR8R928_:R948_R9:RO5:",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Average Average % of answers 7> (column 1)",
      "text": "Row 1:\nEarly Stage",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Average Average % of answers 7> (column 1)",
      "text": "Row 1:\nLocally Advanced Stage",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Average Average % of answers 7> (column 1)",
      "text": "Row 1:\nMetastatic Stage",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Average Average % of answers 7> (column 1)",
      "text": "Row 1:\ntargeted targeted therapy",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Average Average % of answers 7> (column 1)",
      "text": "Row 1:\nDocument quality",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "Average Average % of answers 7> (column 2)",
      "text": "Row 1:\nRowRow 2:\nMiddle% RowRow 3:\n Row 4:\nRowRow 5:\nrow 6: RowRow 7:\nrow 8: Row",
      "start_page": 21,
      "end_page": 21
    },
    {
      "heading": "ESMO ESMO 2023>",
      "text": "Row 1:\nIndicationRow_BCNM Row_RowRrow:RecommendationsRow 2:\nstageMution stageMution __MEDTERM1_(exon 20)CNNM20:CND20:CORD20CNDM20CORD21CEM20NEM20>CNM20",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO ESMO 2023> (column 1)",
      "text": "Row 1:\nIndication",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO ESMO 2023> (column 2)",
      "text": "Row 1:\nBiom",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO ESMO 2023> (column 6)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\nrow row 5: row row 6: row row 7: RowRow 8:\nRowRow 9:\n.",
      "start_page": 25,
      "end_page": 25
    },
    {
      "heading": "ESMO ESMO 2023>",
      "text": "Row 1:\nRowRow 2:\nEnhancement of __Medterm0__/row row 3: Mutation HER2 (ERNB23)RowRow 4:\nCBNP",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "ESMO ESMO 2023>",
      "text": "Row 1:\nIndicationOptional biomarkersRecommendationsRow 2:\nRowRow 3:\nPD-L1 PD-L1 (completely resected tumors)ESSO 2021Rrow 4: stageHigh-level stageHigh-level __Medterm1_Employment:",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "ESMO ESMO 2023> (column 1)",
      "text": "Row 1:\nRowRow 2:\ntherapy therapy therapy",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "ESMO ESMO 2023> (column 1)",
      "text": "Row 1:\nIndicationBiomRow 2:\nRowRow 3:\nMetastatic NSCCL",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "ESMO ESMO 2023> (column 5)",
      "text": "Row 1:\nRowRow 2:\nRowRow 3:\nRowRow 4:\nRowRow 5:\nRowRow 6:\nRowRow 7:\nRowRow 8:\nNCCN 2025",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "ESMO ESMO 2023> (column 5)",
      "text": "Row 1:\nRecommendationsRow 2:\nRowRow 3:\nrow row 4: row row 5: CNSN 2024",
      "start_page": 26,
      "end_page": 26
    },
    {
      "heading": "ESMO ESMO 2023> (from previous page)",
      "text": "Row 1:\nand and __DERM_:_ERM3_,_ERD___BACK__W_S_L_Y_E_T_S",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 1)",
      "text": "Row 1:\nBiomarkersMoleculesRow 2:\nRowRow 3:\nRowRow 4:\n_MEDTERME0_Row 5:\nramucirumab3Row 6:\nRowRow 7:\nFusion involving ___",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 1)",
      "text": "Row 1:\nentrectinib",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 2)",
      "text": "Row 1:\nTypes of authorization",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 2)",
      "text": "Row 1:\nAMMRow 2:\nAMMRow 3:\nnibAAC arrested",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 2)",
      "text": "Row 1:\nAMM",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 2)",
      "text": "Row 1:\nanAMM",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 3)",
      "text": "Row 1:\nRowRow 2:\nfor the CBNP",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 3)",
      "text": "Row 1:\nNoRow 2:\nNoRow 3:\nNo",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 3)",
      "text": "Row 1:\nNo",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 3)",
      "text": "Row 1:\nNo",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 4)",
      "text": "Row 1:\nnceRow 2:\nPC1",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 4)",
      "text": "Row 1:\n Row 2:\nrow 3:",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (column column 4)",
      "text": "",
      "start_page": 27,
      "end_page": 27
    },
    {
      "heading": "ESMO ESMO 2023> (from previous page)",
      "text": "Row 1:\nRowRow 2:\ncapmatinibAMMNoRow 3:\n_MEDTERm2__ammNo",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "ESMO ESMO 2023> (column column 1)",
      "text": "Row 1:\nRowRow 2:\n__MEDSTERM0__Row 3:\n_MEDTERM1__Row 4:\nof of c-_MedTERM3__",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "ESMO ESMO 2023> (column column 2)",
      "text": "Row 1:\nAACYesRow 2:\nAMMNoRow 3:\nRowRow 4:\nAAAC Yes",
      "start_page": 28,
      "end_page": 28
    },
    {
      "heading": "ESMO ESMO 2023> (from previous page)",
      "text": "Row1: MoleculesRow2: Raw2:Rrow3: Row4:MedTERM5_ Row5: following following treatments: ROW6:- Anti-_MEDTERM5-tumours, RowM_: Row Row M:RowRow 21:\nrow row 22:relevant relevant treatment",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "ESMO ESMO 2023> (column column 1)",
      "text": "Row 1:\nMolécuRow 2:\nMutatioRow 3:\nafatinibRow 4:\nerlotiniRow 5:\nGefitinirow 6: osimertRow 7:\ndacomi",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "ESMO ESMO 2023> (column column 2)",
      "text": "Row1: ules Row2: Row2: row2_ Row3: chemopathy Row2 : Row2 Row2 ; Row4: pharmacotherapy Row6: . - or or Row5: metastatic therapy Row7: a a RowM_RowM_TreatmentRegular_RrowM_Chamber:RowD_RownM_Regional_RawM_DeterminationROWM_Delion:RollM_Characterization:RRH_RailM_Layer:ROW_R rowM_RD_D_D;ROL_DR_D:REV_AD_D RawD_RD:OR_Rair_D.Roulion:RowMD_RwM_L:Reachation:RC_Rh_Rhovel_R:RA_R_RR::RT_R+RowRowR_DRood_RJ:B_R,Row_R :Row:N:RB_Rover:RL_Ror:S:MR_RawnM:r:R:R_O_RarM_Rh: R_Rol_Ran_RauationRail_Rough_RH:C:P:R>Row-RowK:ER:CR:RS_Rn_R3RCRx_Rj:E:G:YRHR/R:(R:_Rm_Rice_Ron_Rov_R2:D:RRaal_R&R:I:Q:A_R0R$Rub_R1Rur_RTMRop_RryRum_Rl_R*R:H:R+Rc:M:RhsR orRw:RU:L:Rb_Ry_R30RultureR32Rue_Rhan_R in_Rand_RvRother_Rault_R.R: C_R >R: –R:C:R,Rk:H::RH_C::C_D_CCrowR4:COR+",
      "start_page": 29,
      "end_page": 29
    },
    {
      "heading": "ESMO ESMO 2023> (from previous page)",
      "text": "Row 1:\n__MEDTERM0_Is indicated:Row 2:\n- RowRow 3:\nCBR. CBR.",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "ESMO ESMO 2023> (column column 1)",
      "text": "Row 1:\nramucirRow 2:\namivanRow 3:\nRowRow 4:\ncrizotinRow 5:\nceritinibRow 6:\nalectiniRow 7:\nbrigatinRow 8:\nlorlatin",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "ESMO ESMO 2023> (column column 2)",
      "text": "Row 1:\n Row 2:\nrumabRow 3:\n Row 4:\n Row 5:\nntamaRow 6:\n Row 7:\nimpliqRow 8:\n Row 9:\nnibRow 10:\n Row 11:\n Row 12:\nbRow 13:\n Row 14:\n Row 15:\nibRow 16:\n Row 17:\n Row 18:\nnibbRow 19:\n Row 20:\n Row 21:\nnibbe",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "ESMO ESMO 2023> (column column 3)",
      "text": "Row 1:\nbIs indicated: Row2 : Row3 Row3 :with with CBR_Row7_; Row5: with with docetaxel",
      "start_page": 30,
      "end_page": 30
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)>",
      "text": "Row 1:\nM_D_C_RE_Row_M_S_E_T_N_L_R_R:_Rh_RH_I_W_Y_R_RJ_D _Rh:_O_Rj_Rw_M._P_Rl_Rx_M___Ry_Rho_Rc_Rv_R2_R0_Rf_R1_R+for for non-RJM_BJ_R/RhME_RHO_RQ_Rhe_R",
      "start_page": 31,
      "end_page": 31
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (from previous page)",
      "text": "Row1: Cohormoid_CBNTM_Row_M_Cohort_CDNTM_CBR_CRR_Crow_Cr_CRT_CTR_C_CRL_Crl_CLR_Cral_Cry_Clar_Chr_Cler_CRY_Cycline_Curve_CUR_C:Cr:Cr_D_Cer_Cs Cr_D_Cer_Cs Row:Cry:Cr+Cr__Cr :CryCr in combination:Clar:_Cl_C.Cr>Cr row_Culture_Clin_Cre:C:C_cohord_Cross_Crum_Croes_Cell_Cron_CW_C,Cr(Cr for Row::Curcle_CH_Cher_Cx_Cin::e:::R_Cal_Cor::_R_R:Re:C to_Craft_C;Cr andCrL_CPR_CK_Car_Courn_Ch_CC::A_C/Cr()_CX_Ca_CG_Col_COR_Cw:Crow:CJ:Claw_C >C:R:Cl:Cre_Cloate_C&CrCr fromC_Sr:Craw_Crollation:CR::T_C-CrB_Crs:C.Curv_CCC_Cra_CRE:R:_P_Cll_C$C_:CR_::Chin_C is indicated_Chop:C3_Cen_CiC_RCIn_Cand_Cill_Crew:Chi_C asC_Ch_Clow:C –Cr0:Cop:C orCrN_Cf:Cin_C2:Cub_Cover_Crack_Case_Cred_CCR:CW:Chan_Cau_CRRow 21:\nRowRow 22:\nRowRow 23:\n_MEDTERM_metastatic first line: __MEDDERM7__ __MEDDERM7__ (_MEDTRAM7_-Is indicated)",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 1)",
      "text": "Row 1:\n Row 2:\ndurvaluRow 3:\natezoliz",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 2)",
      "text": "Row 1:\nCouple_CBNTM_Row_M_Couples_Coupon_Crow_CBR_CRR_C_Cr_CRT_CRO_CUR_COR_CTR_CPR_CRL_C:Cr _Cr :Current_CORD_CRD_CRY_CHER_Crop_Cry:CouponD_CHR_Cross_Clar_CJ_Cyctic_Char_Chr: RowRow 21:\nRowRow 22:\nRowRow 23:\n_MEDTERM_metastatic first line: __MEDDERM7__ __MEDDERM7__ (_MEDTRAM7_-Is indicated)",
      "start_page": 32,
      "end_page": 32
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (from previous page)",
      "text": "Row 1:\n__MEDRowM_Cells1N_CELLS1_Cellode3CELLs2COLDS0CBR_C_CRL_CLL_CLR_CTL_CLT_N_D_L1CRL _CRLCLL-CRL:Crl_CLD_CRT_CRR_Cl_C,CLREM_CTR_C.CRYCRD_Cr_CJ_CC_DCORNCCURCRRCDRCORDCCRCRECKCLO_CQCC: CRLRCCLECRBCALLCHERCPRCROCHRCHCHOOLCWECIRCALXBT_COCRUCSTCSC(ECCARTCRESCDECARDCREDPCINCELCULCENPNOCENTCKECSE ICTMOC:AICHNC;CLICCYPOCENCECRON/1 1 :andSGCLEXFRCANDRE andSGCLEXFRCANDRE inCORECTYCLASRICDCCERNTICLOCKC+CROMCLARC>:: RowRow 28:\nor or __METERM8___+ row row 29: . and and __MERM___HOME___; Row",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 1)",
      "text": "Row 1:\ncemipliRow 2:\nnivolumRow 3:\ntislelizuRow 4:\nRowRow 5:\nlarotrecRow 6:\nRepotre",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 2)",
      "text": "Row 1:\n Row 2:\nimabRow 3:\n Row 4:\n Row 5:\nmabRow 6:\n Row 7:\n Row 8:\numabRow 9:\n Row 10:\nimpliqRow 11:\n Row 12:\n_MEDTERm2__Row 13:\n Row 14:\n Row 15:\ne__MEDSTERM2__",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 3)",
      "text": "Row 1:\nof of Row_Row_Cells: row_cells: 1 cell-to-row_chemopathy,1 cell- 0 0 cell- oncology.Row 28:\nor or __METERM3__+ row row 29: . RowRow 30:\n(CHMP Notice 23/02/the the EMA)",
      "start_page": 33,
      "end_page": 33
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (from previous page)",
      "text": "Row 1:\nRow_Blind_CymotherapyRoll_Electromyalgia_Row3_Synthetic_Relationship: Rowl_Ecology_Regional_Treatment:Regular_Tradition:Rrow_Embroidery_Cognition:Combined_Crythematic_Registrat:Cognisess_Residal_Retination:Rollerage_Regeneration:",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (from previous page)",
      "text": "Row 1:\ntrastuzumabRow 2:\nderuxtecan",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (from previous page)",
      "text": "Row1: Molecules Row2: Row2Relationship_Row_Pattern_Roll_Relations: . Row_Related_Roller_Rown_Rrow_Rhine_Rhove_RHO_RH_Rhom_Rhospital_Rheumatism_RHE_Rhoe_Rhormon_R:Rhovel_Rhol_Rhen_Rhemol_Rother_Rwo_Rham_Rhome_Rhan_R+Rhode_Rw_RhyRh_R,Rheal_Rehion_Roma_Rose_R_Rhon_Rcholine_RHC_Rx_Rhire_Rhin_R&Rh for patients:RhM_R;R:Rhoval_RRHor_Rof_Rair_RJH_C_Rough_Rash_Rand_R*Rhence_Rice_Rhu_Rj_R/RhionR_L_Rher_Rov_Rop_Rc_RoxyRhne_R(RhD_R andRhm_Raw_Roff_R row_Rover_R-Rh:Rhe_R :Rh on:RH:RR_Rb_Rex:R:T_R0_R3_Ry_Rhr_Rone_Rv:R_r_Ron_R20:Nh_RRah_C:Row:C:Reh_B:O_R of Rh_K_R>Rhn_R orR’R°R 21Rour_Rcan_R &Rh6Rh in:In_R25_Ration_R to:RCh_G_RTMRum_Render_R hRh,S_R23Rx:OR_R from_Rry_Rth_R's:RD_Rory_RW:P_Riv_R[Rhd_Rear_Rage_Rl_R4_RHA_R24_R",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 1)",
      "text": "Row 1:\nMutatioRow 2:\ncapmatRow 3:\ntepotinRow 4:\nMutatioRow 5:\ntrastuzu bewildered",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 1)",
      "text": "Row 1:\ntrastuzuRow 2:\ndebauched",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 1)",
      "text": "Row 1:\nMolécuRow 2:\nExpressRow 3:\ndurvaluRow 4:\nnivolumRow 5:\nMutatioRow 6:\nmoboce",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 2)",
      "text": "Row 1:\nRowRow 3:\ntherapy therapy (NMCHB)>>> non-chemotherapeutic non-chemotherapeutic therapy: Row_:",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 2)",
      "text": "Row 1:\numabRow 2:\necan",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "PD-L1 PD-L1 (TPS)> (column column 2)",
      "text": "Row1: ules Row2: row17 row17 row",
      "start_page": 34,
      "end_page": 34
    },
    {
      "heading": "of of RET>",
      "text": "Row1: of of Row2: cancer cancer RowM_Advanced_CrowM_RowM: Row3:Column_C rowM_Relational_Patients:Row3:",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "of of RET>",
      "text": "Row 1:\ntelisotuzumabRow 2:\nvedotin (AAC)",
      "start_page": 35,
      "end_page": 35
    },
    {
      "heading": "of of RET>",
      "text": "Row 1:\nrepotrectinibRow 2:\n(AAC)",
      "start_page": 35,
      "end_page": 35
    }
  ]
}